77 results

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera

Tremblay, Douglas; Srisuwananukorn, Andrew; Ronner, Lukas; More

HemaSphere. 6(6):e721, June 2022.

Inflammatory Cytokine Profiles Do Not Differ Between Patients With Idiopathic Cytopenias of Undetermined Significance and Myelodysplastic Syndromes

Nielsen, Amalie Bach; Hansen, Jakob Werner; Ørskov, Andreas Due; More

HemaSphere. 6(5):e0713, May 2022.

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry

Wester, Ruth; Dinmohamed, Avinash G.; van der Holt, Bronno; More

HemaSphere. 6(2):e683, February 2022.

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

Tettero, Jesse M.; Freeman, Sylvie; Buecklein, Veit; More

HemaSphere. 6(1):e676, January 2022.

Improvement of Standardization of Molecular Analyses in Hematology: The 10-year GBMHM French Experience

Alary, Anne Sophie; Maute, Carole; Kosmider, Olivier; More

HemaSphere. 5(12):e658, December 2021.

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients

Estrada, Natalia; Xicoy, Blanca; Beier, Fabian; More

HemaSphere. 5(12):e657, December 2021.

Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal

Valent, Peter; Akin, Cem; Hartmann, Karin; More

HemaSphere. 5(11):e646, November 2021.

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms

Beitzen-Heineke, Antonia; Berenbrok, Nikolaus; Waizenegger, Jonas; More

HemaSphere. 5(9):e630, September 2021.

Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Khalife-Hachem, Sabine; Saleh, Khalil; Pasquier, Florence; More

HemaSphere. 5(9):e632, September 2021.

The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells

van Gils, Noortje; Martiañez Canales, Tania; Vermue, Eline; More

HemaSphere. 5(8):e610, August 2021.

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial

Döhner, Hartmut; Symeonidis, Argiris; Deeren, Dries; More

HemaSphere. 5(8):e617, August 2021.

Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms

Secardin, Lise; Gomez Limia, Cintia; da Silva-Benedito, Suzana; More

HemaSphere. 5(7):e593, July 2021.

Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors

Cucchi, David G. J.; Van Alphen, Carolien; Zweegman, Sonja; More

HemaSphere. 5(7):e606, July 2021.

Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021

Saunders, Jamie; Curto-Garcia, Natalia; Sriskandarajah, Priya; More

HemaSphere. 5(7):e609, July 2021.

Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center

Khan, Alesia; Woodley, Claire; Radia, Deepti; More

HemaSphere. 5(7):e611, July 2021.

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial

Harrison, Claire N.; Schaap, Nicolaas; Vannucchi, Alessandro M.; More

HemaSphere. 5(5):e562, May 2021.

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial

Mesa, Ruben A.; Schaap, Nicolaas; Vannucchi, Alessandro M.; More

HemaSphere. 5(5):e553, May 2021.

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies

Feld, Jonathan; Tremblay, Douglas; Dougherty, Mikaela; More

HemaSphere. 5(4):e549, April 2021.

Next-generation Sequencing in Bone Marrow Failure Syndromes and Isolated Cytopenias: Experience of the Spanish Network on Bone Marrow Failure Syndromes

Gálvez, Eva; Vallespín, Elena; Arias-Salgado, Elena G.; More

HemaSphere. 5(4):e539, April 2021.

Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation

Brauer, Dominic; Backhaus, Donata; Pointner, Rosmarie; More

HemaSphere. 5(3):e532, March 2021.

Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection

Banck, Jan Christoph; Mueller, Niklas; Mellinghoff, Sibylle Christiane; More

HemaSphere. 5(3):e530, March 2021.

Performances of Targeted RNA Sequencing for the Analysis of Fusion Transcripts, Gene Mutation, and Expression in Hematological Malignancies

Hayette, Sandrine; Grange, Béatrice; Vallee, Maxime; More

HemaSphere. 5(2):e522, February 2021.

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

Gisslinger, Heinz; Klade, Christoph; Georgiev, Pencho; More

HemaSphere. 4(6):e485, December 2020.

Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia

Fontana, Diletta; Ramazzotti, Daniele; Aroldi, Andrea; More

HemaSphere. 4(6):e497, December 2020.

Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7

Kunimoto, Hiroyoshi; Fukuchi, Yumi; Murakami, Koichi; More

HemaSphere. 4(5):e469, October 2020.

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience

Mossuto, Sandra; Attardi, Enrico; Alesiani, Francesco; More

HemaSphere. 4(5):e483, October 2020.

Longitudinal Cytokine Profiling Identifies GRO-α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia

Øbro, Nina F.; Grinfeld, Jacob; Belmonte, Miriam; More

HemaSphere. 4(3):e371, June 2020.

Clinical Significance of TARP Expression in Pediatric Acute Myeloid Leukemia

Depreter, Barbara; De Moerloose, Barbara; Vandepoele, Karl; More

HemaSphere. 4(2):e346, April 2020.

Phospho-Profiling Linking Biology and Clinics in Pediatric Acute Myeloid Leukemia

Schumich, Angela; Prchal-Murphy, Michaela; Maurer-Granofszky, Margarita; More

HemaSphere. 4(1):e312, February 2020.

The Pediatric Acute Leukemia Fusion Oncogene ETO2-GLIS2 Increases Self-Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cells-Derived Model

Bertuccio, Salvatore Nicola; Boudia, Fabien; Cambot, Marie; More

HemaSphere. 4(1):e319, February 2020.

Nordic Guidelines for Germline Predisposition to Myeloid Neoplasms in Adults: Recommendations for Genetic Diagnosis, Clinical Management and Follow-up

Baliakas, Panagiotis; Tesi, Bianca; Wartiovaara-Kautto, Ulla; More

HemaSphere. 3(6):e321, December 2019.

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy

Terpos, Evangelos; Kostopoulos, Ioannis V.; Kastritis, Efstathios; More

HemaSphere. 3(6):e300, December 2019.

Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study

Cattaneo, Chiara; Busca, Alessandro; Gramegna, Doriana; More

HemaSphere. 3(6):e320, December 2019.

Is Acute Myeloblastic Leukemia in Children Under 2 Years of Age a Specific Entity? A Report from the FRENCH ELAM02 Study Group

Blais, S.; Boutroux, H.; Pasquet, M.; More

HemaSphere. 3(6):e316, December 2019.

Show: